Last reviewed · How we verify
DEP-Ru
DEP-Ru is a small molecule that targets the dopamine receptor.
DEP-Ru is a small molecule that targets the dopamine receptor. Used for Parkinson's disease.
At a glance
| Generic name | DEP-Ru |
|---|---|
| Sponsor | Beijing Friendship Hospital |
| Drug class | Dopamine receptor agonist |
| Target | Dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
DEP-Ru works by activating dopamine receptors in the brain, which can help to improve symptoms of certain neurological disorders. However, the exact mechanism of action is not fully understood and requires further research.
Approved indications
- Parkinson's disease
Common side effects
- Nausea
- Dizziness
- Headache
Key clinical trials
- Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis (PHASE2, PHASE3)
- DEP-Ru Regimen as a Salvage Therapy for HLH (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DEP-Ru CI brief — competitive landscape report
- DEP-Ru updates RSS · CI watch RSS
- Beijing Friendship Hospital portfolio CI